NASTAD discusses the current landscape of opioid and infectious disease and resources available for health settings to improve screening, testing, and treatment options for patients.
This webinar provides a national perspective of how the hepatitis C virus (HCV) and opioid use disorder epidemics are connected and what health centers can do to address them. We heard from Lauren Canary from the CDC about expansion of medication-assisted treatment (MAT) and what resources are available to providers.
As the Hepatitis C virus (HCV) infection is emerging as a serious public health problem in tandem with the opioid epidemic, health centers have the opportunity to decrease its impact with standardized screening, linkage to care and treatment protocols. This case study highlights how five health centers nationally are addressing the increased rates of HCV infection and its intersection with the opioid epidemic.
October is National Liver Cancer Awareness Month. Join our webinar to discuss how community health centers can use cost-benefit analysis to establish enhanced hepatitis C virus (HCV) screening and testing programs to avoid long-term health impacts for patients. Beginning with a discussion of national trends in HCV rates and an overview of the Viral Hepatitis Action Plan, this webinar features Dr. Michael Halpern from Temple University about cost-benefit analysis and how to apply this method to HCV screening, testing, and treatment within community health centers.
